AIM ImmunoTech (STU:HXB) OCF Margin %: -12,378.95% (As of Mar. 2026)


STU:HXB AIM ImmunoTech Inc STU:HXB
33 GF Score
Price €5.76
GF Value €41.59
! 6 Warning Signs
View Full Analysis

What is AIM ImmunoTech OCF Margin %?

AIM ImmunoTech STU:HXB 33 OCF Margin % is -12,378.95% as of Mar. 2026. GuruFocus rates STU:HXB with a GF Score™ of 33/100 and a GF Value™ of €41.59. The stock has 6 warning signs investors should review. Among 960 Biotechnology companies, AIM ImmunoTech ranks worse than 94.48% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. AIM ImmunoTech's Cash Flow from Operations for the three months ended in Mar. 2026 was €-2.35 Mil. AIM ImmunoTech's Revenue for the three months ended in Mar. 2026 was €0.02 Mil. Therefore, AIM ImmunoTech's OCF Margin % for the quarter that ended in Mar. 2026 was -12,378.95%.

As of today, AIM ImmunoTech's current OCF Yield % is -109.12%.

The historical rank and industry rank for AIM ImmunoTech's OCF Margin % or its related term are showing as below:

STU:HXB' s OCF Margin % Range Over the Past 10 Years
Min: -12451.14   Med: -8389.7   Max: -1817.16
Current: -11977.78

During the past 13 years, the highest OCF Margin % of AIM ImmunoTech was -1817.16%. The lowest was -12451.14%. And the median was -8389.70%.

STU:HXB's OCF Margin % is ranked worse than
94.48% of 960 companies
in the Biotechnology industry
Industry Median: -68.59 vs STU:HXB: -11977.78

AIM ImmunoTech OCF Margin % Related Terms

AIM ImmunoTech OCF Margin % Historical Data

* Premium members only.

The historical data trend for AIM ImmunoTech's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AIM ImmunoTech OCF Margin % Chart

AIM ImmunoTech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10,385.71 -11,433.08 -10,541.62 -8,776.54 -12,476.00

AIM ImmunoTech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14,560.00 -6,031.82 -19,668.18 -9,422.22 -12,378.95

STU:HXB vs BGMS, FBLG, CLGN: OCF Margin % Comparison

For the Biotechnology subindustry, AIM ImmunoTech's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AIM ImmunoTech OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's OCF Margin % distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's OCF Margin % falls into.


STU:HXB
33GF Score
AIM ImmunoTech Inc STU:HXB
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AIM ImmunoTech OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

AIM ImmunoTech's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-9.357/0.075
=-12,476.00 %

AIM ImmunoTech's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-2.352/0.019
=-12,378.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -12,378.95% mean?
AIM ImmunoTech (STU:HXB) has a OCF Margin % of -12,378.95% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on AIM ImmunoTech and its competitors. According to the industry distribution chart, AIM ImmunoTech ranks #907 out of 960 companies in the Biotechnology industry, placing it in the top 94.5%.
Is AIM ImmunoTech's OCF Margin % too high?
AIM ImmunoTech's current OCF Margin % is -12,378.95%. Based on the distribution chart, AIM ImmunoTech ranks #907 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, AIM ImmunoTech has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does AIM ImmunoTech's OCF Margin % compare to BGMS and FBLG?
According to the Biotechnology industry distribution chart, AIM ImmunoTech ranks #907 out of 960 companies for OCF Margin %. This places AIM ImmunoTech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on AIM ImmunoTech and its competitors. AIM ImmunoTech's current OCF Margin % is -12,378.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AIM ImmunoTech stock overvalued right now?
AIM ImmunoTech (STU:HXB) has a current OCF Margin % of -12,378.95%. The stock's GF Value™ is €41.59, compared to a current price of €5.76 — trading 86.1% below its estimated fair value. The current OCF Margin % is -12,378.95%. AIM ImmunoTech's overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For AIM ImmunoTech (STU:HXB), the current OCF Margin % is -12,378.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AIM ImmunoTech (STU:HXB) Overvalued in 2026?

Based on GuruFocus' analysis, AIM ImmunoTech stock appears to be undervalued. The current stock price of €5.76 is trading 86.1% below its estimated GF Value™ of €41.59.

Key valuation signals for STU:HXB:

  • OCF Margin %: -12,378.95%
  • GF Value™: €41.59 vs. price of €5.76 (86.1% below fair value)
  • GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the STU:HXB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AIM ImmunoTech Business Description

Other Exchanges AIM:USA0A4Y:UK
Address 2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
33GF Score

Get the complete analysis for STU:HXB

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.76
Price
€41.59
GF Value